CSL Limited’s AEGIS-II trial of CSL112 fails to meet primary endpoint in heart attack patients
CSL Limited (ASX:CSL; USOTC:CSLLY), a renowned global biotechnology leader, disclosed the top-line outcomes from its eagerly anticipated Phase 3 AEGIS-II trial. This pivotal study assessed ... Read More
Tiziana Life Sciences to launch phase 2 trial of Foralumab in Covid-19
Tiziana Life Sciences said that it plans to launch a phase 2 clinical trial to evaluate the nasal administration of Foralumab in moderate to severe ... Read More
Pfizer’s Lorbrena receives FDA approval for advanced lung cancer treatment
Pfizer Inc., a leading US pharmaceutical company, has secured approval from the US Food and Drug Administration (FDA) for Lorbrena (lorlatinib), a groundbreaking treatment for ... Read More